Introduction {#Sec1}
============

In patients with acute leukemia (AL), long duration and repetitive chemotherapy as well as antimicrobial therapy is believed to contribute to occurrence of infections due to multi-drug resistant (MDR) bacteria in this high-risk group \[[@CR1], [@CR2]\]. In patients with leukemia, because of therapy of their diseases, bacterial infection with MDR Gram-negative bacteria is a real problem that could be associated with a high rate of mortality and morbidity \[[@CR2]--[@CR4]\].

*Citrobacter freundii* is a gram-negative bacterium which is rarely the causative agent of infections but it has been associated with different infections including respiratory, urinary, gastrointestinal and bloodstream infections \[[@CR5], [@CR6]\]. The emergence of MDR *C. freundii,* especially those carbapenemase producing strains, poses a significant threat to public health worldwide, especially in immunocompromised patients such as leukemia patients, which are mostly dependent on antibiotics \[[@CR5], [@CR6]\].

Since the development of new generation sequencing technologies, the access to the full genetic bacterial repertoire has become easier and allow a better understanding the emergence of antibiotic resistance genes on a global scale \[[@CR7], [@CR8]\].

In this study, we applied the whole-genome sequencing to characterize the antibiotic resistance mechanisms of three carbapenem-resistant *C. freundii* clinical isolates recovered from fecal samples of patients with acute leukemia from Spain.

Materials and methods {#Sec2}
=====================

Study design, bacterial isolates and antimicrobial susceptibility test {#Sec3}
----------------------------------------------------------------------

The Study design was described in our previous publication \[[@CR9]\]. A subset of twelve fecal samples, collected between 2013 and 2015 from 9 patients with AL, were screened for the presence of carbapenemase producing (CP) strains by selecting them on MacConkey agar supplemented with ertapenem (0.5 mg/L) \[[@CR10]\]. Cultivated bacteria were identified by matrix-assisted laser desorption ionization--time of flight mass spectrometry (MALDI-TOF MS) (Microflex, Bruker Daltonics, Bremen, Germany). The resistance phenotype of the isolates was evaluated by testing their susceptibly against sixteen antibiotics on Mueller Hinton agar using disk diffusion methodology according to the European Committee on Antimicrobial Susceptibility testing (EUCAST) guidelines (<http://www.eucast.org>). The minimum inhibitory concentration (MIC) of imipenem was determined using Etest method (AB Biodisk, Sweden), the results were interpreted according to the EUCAST breakpoint. The modified Carba NP test method was used to determine a possible carbapenemase production \[[@CR11]\].

Genetic and genomic characterization {#Sec4}
------------------------------------

Real-time and standard PCR were performed to screen for the presence of carbapenem resistance genes, including *bla*~OXA-48~, *bla*~KPC~, *bla*~NDM~ and *bla*~VIM~ \[[@CR12]\]. Whole genome sequencing of the CP strains was performed using the MinION (Oxford Nanopore Technologies Inc., UK) and the MiSeq (Illumina Inc., San Diego, CA, USA) technologies in order to determine the carbapenemase genes variants, the genetic environment, and the genetic support of these genes. The long-read sequencing data generated by Nanopore and short-read data produced by Illumina sequencing were assembled using SPAdes genome assembler \[[@CR13]\]. ARG-ANNOT database available on the ABRicate pipeline and Prokka software were used to identify the antibiotic resistances genes and to annotate genomes, respectively \[[@CR14], [@CR15]\]. Genetic environment has been reconstituted by comparing the sequence of genes surrounding the carbapenemase gene against the NCBI database, using blastX parameter.

Clonal relationship {#Sec5}
-------------------

SNPs analysis (available at <https://cge.cbs.dtu.dk/services/CSIPhylogeny/>) was conducted to study the genomic difference between the three strains and to determine the possible clonal relationship. In order to determine the sequence type (ST) of isolated strains, Multi Locus Sequence Typing (MLST) analysis was performed in silico using the MLST database (available at <https://cge.cbs.dtu.dk/services/MLST/>).

Conjugation experiments and plasmid analysis {#Sec6}
--------------------------------------------

Conjugation was conducted on the three *C. freundii* isolates using azide-resistant *Escherichia coli* J53 as a recipient, as previously described \[[@CR16]\]. The transconjugants were selected on Luria Bertani (LB) agar (Beckton Dickinson, Le Pont de Claix, France) supplemented with sodium azide (120 μg/ml) and Ertapenem (2 μg/ml). Plasmids analysis was performed in silico. Plasmid incompatibility type was identified using PlasmidFinder database (available at <https://cge.cbs.dtu.dk/services/PlasmidFinder/>) and Jspecies Web Server was used to calculate the extent of identity between the plasmids \[[@CR17]\].

### Nucleotide sequence accession number {#Sec7}

The shotgun whole genome sequence of the three *C. freundii* strains and complete sequence of plasmids have been deposited in NCBI GenBank (GenBank accession number CP038653, CP038654, CP038655, CP038656, CP038657, CP038658, CP038659 and CP038660).

Results {#Sec8}
=======

Bacterial strains and microbiological tests {#Sec9}
-------------------------------------------

Three *C. freundii* strains *(C. freundii*\_154, *C. freundii*\_565 and *C. freundii*\_680) were isolated on selective media from fecal samples of three different leukemic patients (Patient-1, Patient-2 and Patient-3) aged 49, 40, 51, respectively (Table [1](#Tab1){ref-type="table"}). All patients received ciprofloxacin prior sampling and only one (Patient-2) received also meropenem (Table [1](#Tab1){ref-type="table"}). Before samples collection, Patient-1 and Patient-2 received an allogenic transplantation, whereas Patient-3 received a high-intensity chemotherapy. The three strains were resistant to most antibiotics tested (Table [2](#Tab2){ref-type="table"}), including carbapenems with imipenem MIC ≥32 μg/ml. All the strains remained susceptible to doxycycline, colistin, fosfomycin and nitrofurantoin. Positive modified Carba NP test results suggested carbapenemase production. Table 1Clinical information about leukemic patients harboring cabapenemase-producing *C. freundii*PatientsAge (years)Hematological malignancy typeSample No.Sampling dateAntimicrobial therapyOther conditions before samplingCP bacteriaPatient_149Acute leukemia15413/02/2014CiprofloxacinTransplantCF_154Patient_240Acute leukemia56524/09/2014Ciprofloxacin, MeropenemTransplantCF_565Patient_351Acute leukemia68026/11/2014CiprofloxacinChemotherapyCF_680*CF C. freundii*, *CP* carbapenemase producing Table 2Analysis of the three *C. freundii* strains isolated from fecal samples of leukemic patientsStrainGenome size (bp)GC%STMIC IPM (mg/L)Sensitive phenotypeResistance phenotypeGenome composition/\
size (bp)ARGsPlasmid typeAccession numberCF_1545,444,81951,5169≥32DOX, CST, FOF, NITAMX, AMC, TZP, CEF, FEP, CRO, ERT, IPM, CIP, AMK, GEN, SXT.CF154_Chromosome/5,143,118*bla*~CMY-81~, *bla*~OXA-48~, *bla*~TEM-150~, *aac3-IId, aph3-Ia, strA, strB, qnrB38, sulII.*/CP038653Plasmid_1 (p154_1)/296,117*bla*~CTX-M-9~, *bla*~SHV-12~, *bla*~VIM-1~, *aac6-Ib-cr, aadA1-pm, aadA2, aadB, qnr-A1, catA1, sulI, dfr16.*IncHI2CP038654Plasmid_2 (p154_2)/5584/ColRNAI_1CP038655CF_5655,471,06551,5169≥32DOX, CST, FOF, NITAMX, AMC, TZP, CEF, FEP, CRO, ERT, IPM, CIP, AMK, GEN, SXT.CF565_Chromosome/5,207,876*bla*~CMY-81~, *bla*~OXA-48~, *bla*~TEM-150~, *aac3-IId, aph3-Ia, strA, strB, qnrB38, sulII.*/CP038656Plasmid_1 (p565_1)/263,189*bla*~CTX-M-9~, *bla*~SHV-12~, *bla*~VIM-1~, *aac6-Ib-cr, aadA1-pm, aadA2, qnr-A1, catA1, sulI, dfr16.*IncHI2CP038657CF_6805,557,66451,4169≥32DOX, CST, FOF, NITAMX, AMC, TZP, CEF, FEP, CRO, ERT, IPM, CIP, AMK, GEN, SXT.CF680_Chromosome/5,167,642*bla*~CMY-81~, *bla*~OXA-48~, *bla*~TEM-150~, *aac3-IId, aph3-Ia, strA, strB, qnrB38, sulII.*/CP038658Plasmid_1 (p680_1)/385,971*bla*~CTX-M-9~, *bla*~OXA-9~, *bla*~SHV-12~, *bla*~TEM-150~, *bla*~VIM-1~, *aac6-Ib-cr, aadA1-pm, aadA2, aadB, qnr-A1, catA1, sulI, dfr16.*IncHI2CP038659Plasmid_2 (p680_2)/4051/ColRNAI_1CP038660*AMX* Amoxicillin, *AMC* Amoxicillin/clavulanic acid, *TZP* Piperacillin + Tazobactam, *CEF* Cephalothin, *FEP* Cefepime, *CRO* Ceftriaxone, *ERT* Ertapenem, *IPM* Imipenem, *CIP* Ciprofloxacin, *AMK* Amikacin, *GEN* Gentamicin, *DOX* Doxycycline, *CST*; Colistin, *FOF* Fosfomycin, *NIT* Nitrofurantoin, *SXT* Sulfamethoxazole/trimethoprim, *MIC* Minimum Inhibitory Concentration, *ARGs* Antibiotic resistance genes, *ST* Sequence Type

Genetic, genomic and molecular epidemiology analysis {#Sec10}
----------------------------------------------------

The genome size of CP *C. freundii* strains obtained after assembly ranged from 5′443'022 and 5′471'065 bp (including chromosome and plasmids for each strains) (Table [2](#Tab2){ref-type="table"}). According to PCR results and genome analysis, carbapenem resistance in these strains was due to the co-production of OXA-48 and VIM-1 carbapenemase enzymes. Resistome analysis showed the presence of genes encoding for resistance to β-lactams, aminoglycosides, quinolones, sulfonamides, trimethoprim and chloramphenicol antibiotics families (Table [2](#Tab2){ref-type="table"}). The gene encoding OXA-48 enzyme was located on the chromosome in the three strains tested and surrounded by the almost similar structures that compose the Tn*1999*.2 transposon (ΔTn1999/IS*1R*-*bla*~OXA-48~-*LysR*-*orf*-ISL3-like) (Fig. [1](#Fig1){ref-type="fig"}.a). Unlike the *bla*~OXA-48~ gene, *bla*~VIM-1~ gene was located in a IncHI-2 plasmid in all the strains. This gene was located in a class 1 integron that contains a new cassette array (*intI1*--*bla*~*VIM-1*~-*aac6-Ib-cr*-*aadA1*-*qqcEΔ1*/*sul1-ΔtniB3-tniA)* (Fig. [1](#Fig1){ref-type="fig"}b). According to the MLST analysis, all strains belonged to the same sequence type, ST169. The SNPs analysis found between 10 and 19 SNPs on average between the three isolates suggesting that these ST169 strains belonged to the same clone. Fig. 1**a** Schematic representation of the genetic environment of the *bla*~OXA-48~ gene located on chromosome and its comparison with the Tn*1999* transposon (JN626286) and its variant Tn*1999.2* (JN714122) and Tn*1999.3* (HE617182). **b** Schematic representation of genes surrounded the *bla*~VIM-1~ gene and the comparison of this genetic environment with that one identified in the Tn*402*-type C

Plasmid conjugation {#Sec11}
-------------------

Conjugation experiments failed for the three strains tested, whereas, in silico plasmids analysis showed the presence of different protein implicated in conjugal transfer and pilus formation but the absences of the plasmid transfer origin (oriT). The comparison of the average nucleotide identity between the three plasmids harboring *bla*~VIM-1~ gene showed that plasmid p154_1 shared 99.99% of similarity with the plasmid p565_1, whereas p680_1 shared 99.94% of similarity with the two other plasmids.

Discussion {#Sec12}
==========

Carbapenemase production in *C. freundii* is poorly documented, only a few studies reported the expression of such enzymes in this species \[[@CR6], [@CR18]--[@CR20]\]. The coproduction of carbapenemase enzymes was already described in some *Enterobacteriaceae* species such as *Klebsiella pneumoniae* (KPC-2 + VIM-2 or NDM-1 + VIM-1) \[[@CR19], [@CR21], [@CR22]\] and *Enterobacter cloacae* (NDM-1 + VIM-1) \[[@CR19]\] as well as in *C. freundii* (KPC-2 + NDM-1, NDM-1 + VIM-1) \[[@CR19], [@CR20]\]. In our study, this situation was observed in three carbapenem resistant *C. freundii* strains detected in fecal samples of three AL patients where, interestingly, two of them didn't received carbapenem as antimicrobial therapy. This suggest that the carbapenem resistance in this context may not be due to a selection pressure with this antibiotic family but it could have been selected by the use of other antibiotic families or by the presence of a carbapenem-resistant clone in the hematological ward, which would explain this current situation.

In Spain, OXA-48 and VIM-1 enzymes are the most prevalent carbapenemase enzymes reported especially in *E. coli*, *E. cloacae* and *K. pneumoniae* \[[@CR18]\]. The coproduction of these two carbapenemase enzymes by *C. freundii* species was reported in only three studies over the world, and only one reported this detection in hematological malignancies patients \[[@CR18], [@CR19], [@CR23]\]. During an unrestricted and non-mandatory national Spanish Antibiotic Resistance Surveillance Programme, undertaken between 2013 and 2015, it has been noted a progressive increase in the rate of *Citrobacter* spp. Carbapenemase-producers, including *C. freundii* species, in Spanish hospital from 1.3% in 2013 to 1.5% in 2015 \[[@CR18]\].

The gene encoding OXA-48 enzyme was mainly related to the Tn*1999* transposon and to its variants \[[@CR24]\]. Our study showed that the *bla*~OXA-48~ gene was located on the chromosome in all strains tested and that its genetic environment was almost identical to that described in Tn*1999.2* variant (Table [2](#Tab2){ref-type="table"}, Fig. [1](#Fig1){ref-type="fig"}a) \[[@CR24]\]. Indeed, the only difference resides downstream of the *bla*~OXA-48~ gene, where this gene was flanked by an ISL3-like in our three *C. freundii* instead of IS*1999* described in Tn*1999.2* variant (Fig. [1](#Fig1){ref-type="fig"}a).

*bla*~VIM-1~ gene was widely detected in different class 1 integrons such as In110 or In113 \[[@CR25]\]. In the study conducted by Arana et al in Spain, *bla*~VIM-1~ identified in their *C. freundii* strains was located on class 1 integrons which include other antibiotics resistant genes such as *aacA4, dfrB1, aadA1*, and *catB2*genes \[[@CR18]\]. Our study also reports the localization of the *bla*~VIM-1~ gene in a class 1 integrons, which contains a new gene cassette, composed of the *bla*~VIM-1~, *aac6-Ib-cr* (conferring resistance to both aminoglycosides and quinolones), *aadA1* (conferring resistance to aminoglycosides) as well as the classic *sulI* gene (Fig. [1](#Fig1){ref-type="fig"}b). The structure of the integrons class 1 type identified in our strains looks like the defective Tn*402* transposon (type C) carrying the *tni* module, ∆*tniB* and *tniA*, reported in the literature (Fig. [1](#Fig1){ref-type="fig"}b) \[[@CR26]\].

In our study, the plasmid carrying the *bla*~VIM-1~ gene identified cannot conjugate, thus excluding the possibility of plasmid dissemination between patients. Moreover, MLST and SNPs analysis showed that the three *C. freundii* strains belonged to the same ST169 clone, which leads us to hypothesize a possible clonal spread of carbapenem-resistant strains in the hematology department.

In this present study, the three *C. freundii* coproducing OXA-48 and VIM-1 carbapenemase enzymes were isolated in a context of digestive carrying and not infectious. It has been shown that in hematological patients, colonization of the digestive tract by carbapenem-resistant bacteria constitutes a risk in the development of infections with these bacteria \[[@CR27]--[@CR29]\]. Despite the fact that our isolates exhibited a high resistance profile, some antibiotics remained active on these bacteria such as doxycycline, colistin, fosfomycin or nitrofurantoin.

Conclusion {#Sec13}
==========

This study reports the clonal spread of *C. freundii* ST169 exhibiting a rare phenotype of co-production of two carbapenemases, namely OXA-48 and VIM-1 enzymes, detected in the digestive tract of patients with acute leukemia. In our opinion, a systematic screening of digestive carriage of antibiotics resistant bacteria would be a great solution to prevent the occurrence of infections due to such bacteria and to control the spread of antibiotic resistance genes, especially within high risk populations.
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